Fit for purpose: treatment optimisation 2014
19 July 2014. Related: Pipeline report, Fit for purpose, Treatment strategies.
Treatment strategies
50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice
27 May 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
PIVOT study: further analysis from five-year PI/r monotherapy strategy study
27 May 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Hospitalisation among elite controllers
27 May 2014. Related: Conference reports, Treatment strategies.
Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs
24 March 2014. Related: Conference reports, Treatment strategies, Drug resistance.
Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)
1 October 2013. Related: Treatment strategies, Treatment access, Guidelines.
Executive summary and research policy recommendations
30 June 2013. Related: Pipeline report, Antiretrovirals, Treatment strategies, Diagnostics, Hepatitis coinfection, TB coinfection.
Retrofitting for purpose: treatment optimisation 2013
30 June 2013. Related: Pipeline report, Fit for purpose, Treatment strategies.
The tuberculosis treatment pipeline
30 June 2013. Related: Pipeline report, Treatment strategies, TB coinfection.
Why the “when to start” question is complex and informed by limited evidence: a response to Dr Myron Cohen
1 April 2013. Related: Treatment strategies, Guidelines.
START study increases sample size: additional 600 participants to be older than 35
1 April 2013. Related: Antiretrovirals, Treatment strategies.
Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors
1 August 2011. Related: Conference reports, Treatment strategies, Basic science and immunology.
Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
Lopinavir/r monotherapy used as second-line therapy in resource-limited settings
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily
1 May 2011. Related: Conference reports, Antiretrovirals, Treatment strategies.
Switching boosted-PIs to raltegravir
1 October 2010. Related: Conference reports, Antiretrovirals, Treatment strategies.
Scaling up: what to do first?
1 October 2010. Related: Conference reports, Treatment strategies, Guidelines.
Tablets more acceptable than syrups in the ARROW trial
26 August 2010. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
Current or former injecting drug use is not related to earlier switch or discontinuation of HAART compared to non-IDU patients since 1999
2 October 2007. Related: Treatment strategies.
HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in people interrupting treatment in the SMART trial: new study to randomise people with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3
3 September 2007. Related: Conference reports, Treatment strategies.
CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r
3 September 2007. Related: Conference reports, Treatment strategies.
Autologous stem cells transplant (ASCT) in HIV-positive individuals with a relapsed non-Hodgkins lymphoma (NHL) or Hodgkins disease (HD)
10 June 2006. Related: Treatment strategies.
Treatment interuption arm in DART trial is stopped early
10 April 2006. Related: Treatment strategies.
Simplification to atazanavir/ritonavir monotherapy
25 March 2006. Related: Conference reports, Treatment strategies.
Summary of STI studies: SMART shows clear increased risk from interrupting treatment at any CD4 count
25 March 2006. Related: Conference reports, Treatment strategies, Coinfections and complications.
Treatment in primary HIV infection
25 March 2006. Related: Conference reports, Treatment strategies.
Therapeutic vaccinations and treatment interruptions
7 March 2006. Related: Treatment strategies.
Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)
13 December 2005. Related: Antiretrovirals, Treatment strategies.
Another chance for 3TC in patients with M184V mutation?
6 September 2004. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.
Kaletra monotherapy: small studies and early data
6 September 2004. Related: Conference reports, Antiretrovirals, Treatment strategies.
Interruption of treatment is safe for those who started too early
1 December 2003. Related: Conference reports, Treatment strategies.
STIs in resource limited settings
1 November 2003. Related: Conference reports, Treatment strategies.
Studies and strategies with existing drugs
1 November 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Treatment interruption prior to five-drug regime shows no benefit at 48 weeks
1 November 2003. Related: Treatment strategies.
Failure of alternating week-on and week-off therapy
1 November 2003. Related: Treatment strategies.
Treatment interruption shows no benefit in drug-resistant HIV infection
1 October 2003. Related: Treatment strategies.
Treatment interruption: a real choice
1 September 2003. Related: Conference reports, Treatment strategies, Lipodystrophy and metabolic complications.
Nucleoside-sparing regimens
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Lessons learned from early HAART in acute HIV infection
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Gender differences in rates and reasons for stopping treatment
1 June 2003. Related: Conference reports, Treatment strategies, Women's health.
Immune reconstitution in older HIV-positive individuals
1 May 2003. Related: Antiretrovirals, Treatment strategies.
Treatment interruptions: cycles, pauses, are just plain stopping?
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment strategies, Hepatitis coinfection, Drug resistance.
Immunology and treatment interruption data presented at the 42nd ICAAC
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruptions may result in poor T-cell recovery in patients with nadir CD+ count <50 cells/mm3
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruptions are safe in patients with CD4+ count between 300 to 500 cells/mm3 and viral loads lower than 70,000 copies/mL
13 November 2002. Related: Conference reports, Treatment strategies.
Treatment interruption strategy reports from the XIV International AIDS Conference
11 September 2002. Related: Conference reports, Treatment strategies.
Aminoperazine shows promise in enhancing immune response of HIV patients
1 October 2001. Related: Treatment strategies.
Interleukin-2 with dual nucleoside therapy
1 October 2001. Related: Treatment strategies.
Immunotherapy at the 1st IAS conference
1 September 2001. Related: Treatment strategies.
Outcome of patients with discordant responses to HAART
17 May 2001. Related: Antiretrovirals, Treatment strategies.
Preliminary data from four studies of double PI regimen using once daily Fortovase plus “mini dose” ritonavir
17 May 2001. Related: Antiretrovirals, Treatment strategies.
Interleukin-2 improves CD4+ cell counts in patients with poor immune response to HAART
17 April 2001. Related: Treatment strategies.
Use of cytokines in HIV: colony-stimulating factors, erythropoietin, and interleukin-2
17 April 2001. Related: Treatment strategies.
Structured treatment interruptions
17 December 2000. Related: Conference reports, Treatment strategies.
Study shows immune system can control HIV: early antiviral treatment primes the immune system to suppress viral levels without drugs
17 October 2000. Related: Treatment strategies, Basic science and immunology.
Human IL-12 may augment HIV-specific immunity in HIV-positive patients
17 October 2000. Related: Treatment strategies.
Structured treatment interruptions and treatment intensification
16 September 2000. Related: Treatment strategies.
New developments in affordable antiretroviral therapy: intermittent treatment
16 August 2000. Related: Conference reports, Treatment strategies.
Once-daily protease-based regimens
16 August 2000. Related: Conference reports, Antiretrovirals, Treatment strategies.
What is the significance of blips in viral load?
16 July 2000. Related: Conference reports, Treatment strategies.